In two subsequent large randomized trials the addition of pembrolizumab, an anti-PD-1 antibody, to the chemotherapeutics significantly increased progression- and overall survival in NSCLC patients [29,30]. Here, PDCD1 is linked to non-small cell lung carcinoma.